This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

Expert opinion: Stivarga® (regorafenib) in focus

Stivarga-BG

Learn about what Stivarga is, how it works and what the key clinical trial data are, as well as Dr Harpreet Wasan’s personal experience of treating patients with Stivarga.

Stivarga Prescribing Information

Strategies for maximising disease control

Hear about Dr Paul Ross’ approach to treating patients through progression of their disease, the role of drug sequencing and how to get the most out of treatment options.

Stivarga Prescribing Information

Speakers
    • harpreet_wasan
      Dr Harpreet Wasan

    Dr Harpreet Wasan is a Professor in Medical Oncology and leads the gastrointestinal clinical research program at Hammersmith Hospital, Imperial College London and is current Lead for Cancer for The N.W. London NIHR Research network. His research interests cover CRC, Biliary, Pancreatic Cancer & CUP and has led and participated in trials that have led to global new standards of care with interests in designing and implementing novel paradigm & interventional trials (including non-drug interventions) in GI cancer.

    • paul_ross
      Dr Paul Ross

    Dr Paul Ross is a Consultant Medical Oncologist at Guy’s & St Thomas’ and King’s College Hospitals. He specialises in HPB and colorectal cancers. He has served on national groups including: NCRI Upper GI Cancers Clinical Studies group, its hepato-biliary sub-group; NCRI CRC adjuvant & advanced disease group; NHSEs Chemotherapy Clinical Reference group; Association of Cancer Physicians. His research interests are focussed around pharmacogenomics, interventional oncology and clinical trials. Paul trained at the Royal Marsden Hospital and Institute of Cancer Research. His Research was awarded the Association of Cancer Physicians McElwain prize and an American Society of Clinical Oncology Merit award.

Ask the experts: Three key questions on mCRC
Stivarga® (regorafenib)
PP-STI-GB-0205, February 2024
The treatment landscape in mCRC
Stivarga® (regorafenib)
PP-STI-GB-0202, February 2024
UKOF 2023 Symposium
Stivarga® (regorafenib)
PP-STI-GB-0274, February 2024

PP-STI-GB-0200 | February 2024